AI Article Synopsis
- * Treatment options for neuropathic pain in MS include a mix of pharmacological strategies (like cannabinoids, muscle relaxants, anticonvulsants, antidepressants, and opioids) and non-pharmacological methods (such as physical therapy and psychotherapy).
- * Effective pain management in MS depends on factors like pain type and severity, patient preferences, and any existing health conditions, highlighting the need for improved strategies by healthcare professionals and researchers.
Article Abstract
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte's phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40263-024-01072-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Extranasal Neurostimulation for Patients With Neuropathic Corneal Pain: A Pilot Study.
Cornea
October 2024
Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; and.
Purpose: Neuropathic corneal pain (NCP) has been recognized as a distinct disease, yet treatment options remain limited. The aim of this pilot study was to explore the effectiveness of extranasal neurostimulation (EXNS) as a potential pain relief strategy for individuals with the peripheral component of NCP.
Methods: A retrospective study was performed to identify patients who were diagnosed with refractory peripheral or mixed NCP and subsequently underwent a single session of EXNS.
A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer.
Pediatr Phys Ther
January 2025
University of North Dakota School of Medicine, Department of Pediatrics, Grand Forks, North Dakota (Ms Washist and Dr Milanovich); Sanford Children's Hospital, Department of Physical Therapy, Sioux Falls, South Dakota (Dr Steventon); Sanford Children's Hospital, Department of Physical Therapy, Fargo, North Dakota (Dr Samuelson); Jamestown University, Department of Physical Therapy, Jamestown, North Dakota (Dr Anderson); University of South Dakota, Department of Physical Therapy, Vermillion, South Dakota (Dr Berg-Poppe); and Sanford Roger Maris Cancer Center, Department of Pediatric Hematology and Oncology, Fargo, North Dakota (Dr Milanovich).
Unlabelled: Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) with associated weakness, areflexia, neuropathic pain, and sensory loss, is a common occurrence in children treated for cancer. However, accurate, quantifiable descriptions of gait deviations due to CIPN are lacking. This scoping review explores common gait abnormalities in children with CIPN.
View Article and Find Full Text PDFDorsal Root Ganglion Stimulation for Chronic Pelvic Pain Secondary to Endometriosis.
Neuromodulation
December 2024
Functional and Pain Clinic, Sao Paulo, SP, Brazil; Pediatric Neurosurgery, Washington University in St. Louis, St Louis, MO, USA. Electronic address:
Introduction: Chronic pelvic pain (CPP) is a multifaceted condition that poses significant challenges in clinical management owing to its complex and varied pathophysiology, including neuropathic, somatic, visceral, and musculoskeletal components. Endometriosis is frequently associated with CPP, necessitating a comprehensive, multimodal treatment strategy. This approach typically includes physical and behavioral therapy, pharmacologic interventions, surgical management of endometriosis, and various pain-modulating procedures.
View Article and Find Full Text PDFExtract and Its Active Metabolite α-Cyperone Alleviates Paclitaxel-Induced Neuropathic Pain via the Modulation of the Norepinephrine Pathway.
Metabolites
December 2024
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Republic of Korea.
Background: Paclitaxel is a widely used anticancer drug for ovarian, lung, breast, and stomach cancers; however, its clinical use is often limited by the side effects of peripheral neuropathy. This study evaluated the effects of () extract and its active metabolite, α-cyperone, on paclitaxel-induced neuropathic pain.
Methods: The oral administration of extract at doses of 500 mg/kg and intraperitoneal administration of α-cyperone at doses of 480 and 800 μg/kg prevented both the development of cold and mechanical pain.
Methadone in Cancer-Related Neuropathic Pain: A Narrative Review.
Curr Oncol
December 2024
Division of Palliative Medicine, Department of Internal Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Cancer-related neuropathic pain (CRNP) is often a significant burden on patients' quality of life. There are limited treatment guidelines for cancer-related neuropathic pain outside of CIPN. Although opioids are considered a third-line treatment option, no consensus exists on which opioid is most effective, either as a single agent or in combination with other medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!